Brincidofovir (Synonyms: CMX001; HDP-CDV)

Name: Brincidofovir
Brand: MedChemExpress
SKU: HY-14532
Rating: 5.0 (2 reviews)

Cat. No.: HY-14532 Purity: 99.00%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438), is an orally available, long-acting antiviral. Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo..

For research use only. We do not sell to patients.

Brincidofovir Chemical Structure

CAS No. : 444805-28-1

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 2 publication(s) in Google Scholar

2 Publications Citing Use of MCE Brincidofovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

EC50: 5.5 nM (anti-CMV, in PDA at 7 dpi)

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	EC₅₀	0.125 μM Compound: 1, HDP-CDV	Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Ectromelia virus Moscow infected in african green monkey BSC1 cells after 4 to 5 days by plaque reduction assay	[PMID: 21493074]
BSC-1	CC₅₀	25.3 μM Compound: 1, HDP-CDV	Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay Cytotoxicity against african green monkey BSC1 cells after 2 to 4 hrs by MTS assay	[PMID: 21493074]
HFF	EC₅₀	0.08 μM Compound: 1, HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Vaccinia virus Copenhagen infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.13 μM Compound: CMX001	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.14 μM Compound: CMX001	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.2 μM Compound: 1, HDP-CDV	Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay Antiviral activity against Cowpox virus (Brighton Red) infected in human HFF cells after 3 days by plaque reduction assay	[PMID: 21493074]
HFF	EC₅₀	0.24 μM Compound: CMX001	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction plaque formation after 3 days	[PMID: 17724153]
HFF	EC₅₀	0.6 μM Compound: HDP-CDV	Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Cowpox virus Brighton in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	0.8 μM Compound: HDP-CDV	Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus Copenhagen in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	EC₅₀	1.1 μM Compound: HDP-CDV	Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days Antiviral activity against Vaccinia virus WR in HFF cells assessed as reduction of viral replication after 3 days	[PMID: 17846137]
HFF	CC₅₀	25 μM Compound: 1, HDP-CDV	Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay Cytotoxicity against human HFF cells assessed as reduction in cell viability after 7 days by neutral red uptake assay	[PMID: 21493074]
HFF	CC₅₀	31 μM Compound: HDP-CDV	Cytotoxicity against HFF cells after 7 days Cytotoxicity against HFF cells after 7 days	[PMID: 17846137]
HFF	CC₅₀	42 μM Compound: CMX001	Cytotoxicity against HFF cells after 7 days by neutral red assay Cytotoxicity against HFF cells after 7 days by neutral red assay	[PMID: 17724153]

In Vivo

Brincidofovir (BCV) (20 mg/kg; p.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24) extends survival in immune-deficient BALB/c nu/nu mice following lethal challenge with IHD-J-Luc VACV^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	BALB/c nu/nu mice (infected with IHD-J-Luc VACV)^[3]
Dosage:	20 mg/kg
Administration:	P.o.; on days 1, 3, 5, 7, 10, 14, 17, 21, and 24
Result:	On days 1, 3, and 5 maintained their weights initially but started to lose weight beginning on day 9 and succumbed between days 24 and 29 postchallenge.

Clinical Trial

Molecular Weight

561.69

Formula

C₂₇H₅₂N₃O₇P

CAS No.

444805-28-1

Appearance

Solid

Color

White to off-white

SMILES

NC1=NC(N(C[C@@H](CO)OCP(O)(OCCCOCCCCCCCCCCCCCCCC)=O)C=C1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 1 mg/mL (1.78 mM; adjust pH to 8 with NaOH and heat to 50°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.7803 mL	8.9017 mL	17.8034 mL
5 mM	---	---	---
10 mM	---	---	---

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Purity: 99.00%

Select Batch:

Data Sheet (269 KB) SDS (393 KB)

COA (241 KB) HNMR (279 KB) RP-HPLC (263 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Hiwarkar P, et al. Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017;129(14):2033-2037. [Content Brief]

[2]. Detweiler CJ, et al. Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. J Pediatr Hematol Oncol. 2018;40(6):e364-e368. [Content Brief]

[3]. Zaitseva M, McCullough KT, Cruz S, et al. Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus. J Virol. 2015;89(6):3295-3307. [Content Brief]

[4]. Scott A Foster , et al. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak. Viruses. 2017 Oct 30;9(11):320. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO

1 mM

1.7803 mL

8.9017 mL

17.8034 mL

44.5085 mL

Brincidofovir Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Brincidofovir (Synonyms: CMX001; HDP-CDV)

Customer Review

Brincidofovir Related Antibodies

2 Publications Citing Use of MCE Brincidofovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Brincidofovir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report